Dr. Apelian has previously served as clinical director of infectious disease at Bristol-Myers Squibb, New York-based biopharmaceutical company, and clinical director of hepatology and gastroenterology at Schering Plough, New Jersey-based pharmaceutical company that has since merged with Merck & Co.
He will head the clinical development of Achillion’s hepatitis C treatments.
More Articles on Gastroenterology:
Vision-Sciences Names Howard Zauberman Interim CEO
Dr. Allen Kamrava to Invest, Practice at La Peer Health Systems
Dr. Roger Klein Joins Summit Medical Group
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
